Endocrine Society GUIDELINES Bundle (free trial)

Metabolic Risk

Endocrine Society GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/302967

Contents of this Issue


Page 16 of 17

17 Blood Pressure Reduction ➤ 3.7: In individuals with blood pressure above 130/80 mmHg and a ten-year cardiovascular risk <10%, ES suggests lifestyle management to lower blood pressure to <130/80 mmHg and to reduce the risk for ASCVD. (2|⊕⊕⊕ ) Technical Remarks: ▶ Since the 10-year risk is ≤10%, lifestyle intervention is appropriate and preferable to use of medications. ▶ Interventions include weight loss, healthy diet, sodium restriction, enhanced potassium intake, increased physical activity, and moderation of alcohol use. ➤ 3.8: In individuals without a history of ASCVD with metabolic risk who have a 10-year cardiovascular risk of >10% and blood pressure of >130/80 mmHg, ES suggests the use of blood pressure-lowering medication in addition to lifestyle modifications for primary prevention of ASCVD only if lifestyle modification alone has failed. (2|⊕⊕⊕ ) Reducing Progression to Type 2 Diabetes ➤ 3.9: In individuals with prediabetes, ES recommends prescribing lifestyle modification before drug therapy to reduce plasma glucose levels. (1|⊕⊕⊕⊕) ➤ 3.10: In individuals with prediabetes who have limitations to physical activity or are not responding to lifestyle modifications, ES recommends metformin as a first pharmacologic approach to reduce plasma glucose levels. (1|⊕⊕⊕ )

Articles in this issue

Archives of this issue

view archives of Endocrine Society GUIDELINES Bundle (free trial) - Metabolic Risk